Browse hierarchy: [Clinical Toxicology (TX)](/submissions/TX) → [Subpart D — Clinical Toxicology Test Systems](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems) → [21 CFR 862.3100](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/862.3100) → DJP — Radioimmunoassay, Amphetamine

# DJP · Radioimmunoassay, Amphetamine

_Clinical Toxicology · 21 CFR 862.3100 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP

## Overview

- **Product Code:** DJP
- **Device Name:** Radioimmunoassay, Amphetamine
- **Regulation:** [21 CFR 862.3100](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/862.3100)
- **Device Class:** 2
- **Review Panel:** [Clinical Toxicology](/submissions/TX)
- **3rd-party reviewable:** yes

## Identification

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

## Classification Rationale

Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

## Special Controls

*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

## Recent Cleared Devices (9 of 9)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K960526](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K960526.md) | PRIMIDONE EIA TEST | Diagnostic Reagents, Inc. | Mar 18, 1996 | SESE |
| [K913866](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K913866.md) | URINE AMPHETAMINE DIRECT RIA KIT (I-125) | Immunalysis Corporation | Sep 25, 1991 | SESE |
| [K912755](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K912755.md) | ABUSCREEN RADIOIMMUNOASSAY FOR AMPHETAMINE | Roche Diagnostic Systems, Inc. | Aug 26, 1991 | SESE |
| [K882228](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K882228.md) | REVISED DOUBLE ANTIBODY AMPHETAMINE | Diagnostic Products Corp. | Aug 8, 1988 | SESE |
| [K881817](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K881817.md) | ABUSCREEN(R) ONTRAK(TM) FOR AMPHETAMINES | Roche Diagnostic Systems, Inc. | Jul 29, 1988 | SESE |
| [K854009](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K854009.md) | ABUSCREEN RADIOIMMUNOASSAY FOR AMPHETAMINE-HIGH SP | Roche Diagnostic Systems, Inc. | Oct 15, 1985 | SESE |
| [K830482](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K830482.md) | ABUSCREEN RADIOIMMUNOASSAY-AMPHETAMINE | Hoffmann-La Roche, Inc. | Mar 24, 1983 | SESE |
| [K823212](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K823212.md) | ABUSCREEN RADIOIMMUNOASSAY - AMPHETAMINE | Hoffmann-La Roche, Inc. | Nov 29, 1982 | SESE |
| [K812986](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP/K812986.md) | AGGLUTEX AMPHETAMINE TEST KIT | Hoffmann-La Roche, Inc. | Jan 22, 1982 | SESE |

## Top Applicants

- Hoffmann-La Roche, Inc. — 3 clearances
- Roche Diagnostic Systems, Inc. — 3 clearances
- Diagnostic Products Corp. — 1 clearance
- Diagnostic Reagents, Inc. — 1 clearance
- Immunalysis Corporation — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DJP)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com